Paul Matthews, OBE, MD, DPhil, FRCP, FMedSci is Head of the Department of Brain Sciences in the Faculty of Medicine of Imperial College London. He is Head of the UK Dementia Research Institute at Imperial and an Associate Director of the UK Dementia Research Institute nationally.
His early research addressed innovative translational applications of clinical imaging for the neurosciences. This has developed with exploitation of the powerful synergies between the physical and quantitative sciences and medicine. His was the founding Director of two internationally leading research imaging centres, the University of Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB) and, later, of GlaxoSmithKline’s Clinical Imaging Centre (now a public “spin out” as Imanova, Ltd). From 2005 - 2014 he was a Vice President GlaxoSmithKline Medicines Discovery and Development. With this experience, he became one of the small number of senior clinical academics in the UK with industry experience.
He has continued his interests in imaging in several ways, including as Chair of the Imaging Working Group for UK Biobank, which is pioneering an ambitious programme for very large population imaging as part of the UK Biobank (Prof Sir Rory Collins, CEO). MRI scanning of the brain, heart and body, along with DEXA and 3D carotid ultrasound, was initiated in a dedicated imaging centre at UK Biobank's Cheadle (Manchester) site in May, 2014. This has developed into a broader commitment to large data analytics through collaborative work with colleagues in the Imperial College Data Science Institute and the EPSRC Centre for Mathematics in Precision Healthcare, in which he is a co-investigator.
Led by a series of studies of glial dynamics in human disease using PET, his group recently has expanded work to elucidate roles of microglia and astrocytes in neurodegeneration in the context of both multiple sclerosis and Alzheimer's disease. A wide range of methods now are being integrated with imaging, including 'omics strategies deployed minimally invasively in blood and in isolated brain tissue post mortem.
Amongst many external commitments, Professor Matthews is Chair of the MRC Neurosciences and Mental Health Board and a member of the Executive Committee for the UK Dementias Platform, the Steering Committee for UK Biobank, the Netherlands Organisation for Scientific Research Spinoza Prize Committee, the Japanese RIKEN Brain Dynamics Research Centre Advisory Council and the Canadian Multiple Sclerosis Society Medical Advisory Committee. He is a Fellow by Special Election of St Edmund Hall, Oxford, and a Visiting Professor in the University of Oxford, McGill University and Nanyang University's LKC School of Medicine.
et al., 2023, Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases, Nature Communications, Vol:14, ISSN:2041-1723, Pages:1-25
et al., 2023, The association between brain volume loss and disability in multiple sclerosis: A systematic review., Mult Scler Relat Disord, Vol:74
et al., 2023, Circulatory proteins relate cardiovascular disease to cognitive performance: a Mendelian randomisation study, Frontiers in Genetics, Vol:14, ISSN:1664-8021, Pages:1-11
et al., 2023, Inflammatory diseases, inflammatory biomarkers, and Alzheimer disease: an observational analysis and mendelian randomization, Neurology, Vol:100, ISSN:0028-3878, Pages:e568-e581
et al., 2023, Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy., Medrxiv